A powerful immune-suppressing molecule produced by the body may hold the key to better treatments for autoimmune and inflammatory diseases, as well as for some cancers, according to a study by researchers at Weill Cornell Medicine and the University of Perugia.
Artificial intelligence in cancer research, diagnosis & therapy
September 20, 2021
“Artificial intelligence in cancer research, diagnosis and therapy,” a Viewpoint article from Nature Reviews Cancer, September 17, 2021.
In this Viewpoint article, Nature Reviews Cancer asked four experts for their opinions on how we can begin to implement artificial intelligence while ensuring standards are maintained so as transform cancer diagnosis and the prognosis and treatment of patients with cancer and to drive biological discovery.
An Ambitious New Plan to Change Medicine
September 15, 2021
Medicine is at a watershed moment: decades of technological advances have revealed unprecedented insights into human biology and how various physiological, genetic and lifestyle factors shape health. These findings have laid the groundwork for enduring change in medicine—an opportunity Weill Cornell Medicine is seizing with its June 17 launch of We’re Changing Medicine, a campaign to raise $1.5 billion for an expansive vision of medicine that will make a global impact.
September 2021 EIPM Director's Memo
September 7, 2021
Dear Members of the Englander Institute,
I’m very proud of our work over the past month, including enviable news media coverage in publications like The New York Times, the awards and grants we’ve earned, and research published in high-profile journals like The New England Journal of Medicine.
The Future? Mixed-reality headsets in I.C.U.s
August 30, 2021
Meet you in the metaverse, maybe
Facebook’s virtual reality service Horizon Workrooms, announced this month, will allow users to don a VR headset, create an avatar and sit among colleagues in computer-generated corporate settings. It’s not the only company betting on enterprise VR.
Key Immune Cells Maintain Healthy Gut Bacteria
August 17, 2021
Key Immune Cells Maintain Healthy Gut Bacteria to Protect Against Colorectal Cancer
An immune cell subset called innate lymphoid cells (ILC3s) protects against colorectal cancer, in part by helping to maintain a healthy dialogue between the immune system and gut microbes, according to a new study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian. The finding opens the door to new strategies for treating this type of cancer.
August 2021 EIPM Director’s Memo
August 4, 2021
Dear Members of the Englander Institute,
I hope you’re enjoying the summer and continuing to stay healthy. We are closely monitoring the rise of the Delta variant, and encourage everyone to get vaccinated and to follow the new requirements from Dean Choi about wearing your mask on campus.
New Treatment Option for Advanced Bladder Cancer
August 2, 2021
A new treatment for advanced urothelial cancer was effective with tolerable side effects in an international, multi-center phase 2 clinical trial led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
The trial results prompted a U.S. Food and Drug Administration (FDA) accelerated approval of the treatment on April 13, giving patients with this very aggressive type of cancer a new therapeutic option.
Vaccine Improves Outcomes in Lynch Syndrome Model
July 29, 2021
Cancer Vaccine Improves Outcomes in Lynch Syndrome Model
A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led by scientists at Weill Cornell Medicine, NewYork-Presbyterian and Heidelberg University Hospital. The preclinical results could eventually lead to vaccines that cause the immune system to target cancers early in their development, preventing the disease from becoming established.
Trial Shows Cell Therapy May Prevent Infections in Patients
July 16, 2021
Treatment with a ready-made preparation of human immune cells helps prevent infections in people whose immune systems are temporarily weakened by leukemia treatment, according to a phase 2 clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian. Infections are a significant problem in patients undergoing chemotherapy for cancer.